704 related articles for article (PubMed ID: 31560051)
21. Impact of oral vancomycin treatment duration on rate of
Kwiatkowski D; Marsh K; Katz A; Papadopoulos J; So J; Major VJ; Sommer PM; Hochman S; Dubrovskaya Y; Arnouk S
Infect Control Hosp Epidemiol; 2024 Jun; 45(6):717-725. PubMed ID: 38288606
[TBL] [Abstract][Full Text] [Related]
22. The Effect of Saccharomyces boulardii Primary Prevention on Risk of Hospital-onset Clostridioides difficile Infection in Hospitalized Patients Administered Antibiotics Frequently Associated With C. difficile Infection.
Wombwell E; Patterson ME; Bransteitter B; Gillen LR
Clin Infect Dis; 2021 Nov; 73(9):e2512-e2518. PubMed ID: 32575126
[TBL] [Abstract][Full Text] [Related]
23. An Open-Label, Randomized Trial Comparing Fidaxomicin With Oral Vancomycin for the Treatment of Clostridioides difficile Infection in Hospitalized Patients Receiving Concomitant Antibiotics for Concurrent Infections.
Rao K; Zhao Q; Bell J; Krishnan J; Henig O; Daniel J; Sawaya K; Albin O; Mills JP; Petty LA; Gregg K; Kaul D; Malani AN; Pogue J; Kaye KS
Clin Infect Dis; 2024 Feb; 78(2):277-282. PubMed ID: 37797310
[TBL] [Abstract][Full Text] [Related]
24. Using diagnostic stewardship to reduce rates, healthcare expenditures and accurately identify cases of hospital-onset
Solanky D; Juang DK; Johns ST; Drobish IC; Mehta SR; Kumaraswamy M
Infect Control Hosp Epidemiol; 2021 Jan; 42(1):51-56. PubMed ID: 32943129
[TBL] [Abstract][Full Text] [Related]
25. Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients.
Ganetsky A; Han JH; Hughes ME; Babushok DV; Frey NV; Gill SI; Hexner EO; Loren AW; Luger SM; Mangan JK; Martin ME; Smith J; Freyer CW; Gilmar C; Schuster M; Stadtmauer EA; Porter DL
Clin Infect Dis; 2019 May; 68(12):2003-2009. PubMed ID: 30256954
[TBL] [Abstract][Full Text] [Related]
26. Houston, We Have a Problem: Reports of Clostridioides difficile Isolates With Reduced Vancomycin Susceptibility.
Greentree DH; Rice LB; Donskey CJ
Clin Infect Dis; 2022 Oct; 75(9):1661-1664. PubMed ID: 35653393
[TBL] [Abstract][Full Text] [Related]
27. [Clostridioides difficile - New Insights and Therapy Recommendations].
Schönherr S; Jung L; Lübbert C
Dtsch Med Wochenschr; 2023 Jun; 148(12):752-758. PubMed ID: 37257477
[TBL] [Abstract][Full Text] [Related]
28. Impact of Clostridioides difficile length of treatment on rates of recurrence in patients on concurrent antibiotics.
Rajakumar I; Jaber R; Ali R; Rennert-May E; Sabuda D
Am J Infect Control; 2023 Nov; 51(11):1213-1217. PubMed ID: 37105356
[TBL] [Abstract][Full Text] [Related]
29. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE).
Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R
Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143
[TBL] [Abstract][Full Text] [Related]
30. Ridinilazole: a novel, narrow-spectrum antimicrobial agent targeting Clostridium (Clostridioides) difficile.
Collins DA; Riley TV
Lett Appl Microbiol; 2022 Sep; 75(3):526-536. PubMed ID: 35119124
[TBL] [Abstract][Full Text] [Related]
31. Saccharomyces boulardii prophylaxis for targeted antibiotics and infectious indications to reduce healthcare facility-onset Clostridioides difficile infection.
Wombwell E
Microbes Infect; 2023; 25(3):105041. PubMed ID: 36058513
[TBL] [Abstract][Full Text] [Related]
32. Healthcare facility-onset, healthcare facility-associated
Evans CT; Fitzpatrick M; Ramanathan S; Kralovic SM; Burns SP; Goldstein B; Smith B; Gerding DN; Johnson S
J Spinal Cord Med; 2020 Sep; 43(5):642-652. PubMed ID: 31663843
[No Abstract] [Full Text] [Related]
33. Clostridioides (Clostridium) difficile infection in Japanese hospitals 2008-2017: A real-world nationwide analysis of treatment pattern, incidence and testing density.
Kimura T; Stanhope S; Sugitani T
J Infect Chemother; 2020 May; 26(5):438-443. PubMed ID: 32081648
[TBL] [Abstract][Full Text] [Related]
34. Assessing the Impact of 2-Step Clostridioides difficile Testing at the Healthcare Facility Level.
Turner NA; Krishnan J; Nelson A; Polage CR; Cochran RL; Fike L; Kuhar DT; Kutty PK; Snyder RL; Anderson DJ
Clin Infect Dis; 2023 Oct; 77(7):1043-1049. PubMed ID: 37279965
[TBL] [Abstract][Full Text] [Related]
35. A prospective, observational study of fidaxomicin use for
Guery B; Berger P; Gauzit R; Gourdon M; Barbut F; ; Dafne Study Group ; Bémer P; Bessède E; Camou F; Cattoir V; Couzigou C; Descamps D; Dinh A; Laurans C; Lavigne JP; Lechiche C; Leflon-Guibout V; Le Monnier A; Levast M; Mootien JY; N'Guyen Y; Piroth L; Prazuck T; Rogeaux O; Roux AL; Vachée A; Vernet Garnier V; Wallet F
J Int Med Res; 2021 Jun; 49(6):3000605211021278. PubMed ID: 34162264
[TBL] [Abstract][Full Text] [Related]
36. Surveillance and epidemiology of Clostridioides difficile infection using the national health surveillance network criteria: A 7-year study from Mumbai, India.
Rohra S; Poojary A; Patil P; John S; Michael R; Johnson S; Pardeshi P
Indian J Med Microbiol; 2023; 46():100425. PubMed ID: 37945118
[TBL] [Abstract][Full Text] [Related]
37. Epidemiology of
Kaabia NM; Al Basha H; Bukhari DA; Bouafia N; Al Qahtani AN; Alshahrani AM; Aboushanab IM; Al Odayani AN
Saudi Med J; 2024 Feb; 45(2):188-193. PubMed ID: 38309732
[TBL] [Abstract][Full Text] [Related]
38. Increase of healthcare-onset Clostridioides difficile infection in adult population since SARS-CoV-2 pandemic: A retrospective cohort study in a tertiary care hospital from 2019 to 2022.
Maldonado-Barrueco A; Moreno-Ramos F; Díaz-Pollán B; Loeches-Yagüe B; Rico-Nieto A; García-Rodríguez J; Ruiz-Carrascoso G
Anaerobe; 2024 Apr; 86():102836. PubMed ID: 38428802
[TBL] [Abstract][Full Text] [Related]
39. Differences in time-to-testing and time-to-isolation between community-onset and hospital-onset Clostridioides difficile cases at a tertiary care VA medical center.
Hostler CJ; Bertumen JB; Park LP; Wilkins SB; Woods CW
Am J Infect Control; 2020 Oct; 48(10):1148-1151. PubMed ID: 31911067
[TBL] [Abstract][Full Text] [Related]
40. Antibiotic Exposure and Risk for Hospital-Associated Clostridioides difficile Infection.
Webb BJ; Subramanian A; Lopansri B; Goodman B; Jones PB; Ferraro J; Stenehjem E; Brown SM
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964789
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
